FN1 and melanoma: In this investigation when a low dose of fisetin and sorafenib were combined, combination treatment exhibited greater reduction in mesenchymal marker protein expression (N-cadherin, vimentin and fibronectin) and potentiated upregulation of epithelial marker protein expression (E-cadherin) in BRAF mutated melanoma cells in both in vitro and in vivo xenograft tumors.